A Study of Efavirenz in Combination With Stavudine and Didanosine

Inclusion Criteria Patients must have: * Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml. * A life expectancy of at least 12 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current bilateral peripheral neuropathy greater than or equal to Grade 2. * Any clinically significant laboratory findings obtained during the screening evaluation (see laboratory values). * Any clinically significant disease (other than HIV infection) or clinically significant findings during screening of medical history or physical examination. * Any malignancy that requires systemic therapy. * Proven or suspected acute hepatitis due to any cause. * Recurrent episodes of moderate to severe diarrhea, or vomiting lasting more than 4 days within 3 months prior to dosing. * Active AIDS-defining opportunistic infection or disease. Concurrent Medication: Excluded: Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin, rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine. Patients with the following prior conditions are excluded: * History of acute or chronic pancreatitis. * Life expectancy less than 12 months. * Difficulty in swallowing capsules/tablets. * Hypersensitivity to any component of the formulation of efavirenz, stavudine, or didanosine. Prior Medication: Excluded: * Any other experimental drug within 30 days of introducing study treatment. * Vaccination within 3 weeks of screening visit. * Interferon started within 30 days of initiating study treatment. * Prior antiretroviral therapy. Risk Behavior: Excluded: \- Current alcohol or illicit drug use which would interfere with compliance with dosing schedule and protocol evaluations.